2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi

M-J. Ahn, T.M. Kim, L. Bonanno, Sierra Cheng, S-W. Kim, M. Tiseo, Q.S-C. Chu, Claudia Proto, A. Sacher, Y-H. Luo, C.S. Baik, Lyudmila Bazhenova, J. Cadranel, D. Bao Tuan, P R Narayanan, J.C-H. Yang, Alexander Gont, Mark E. Haskins, Wei Xu, F. De Marinis